Adebrelimab plus capecitabine versus capecitabine monotherapy for adjuvant treatment of high-risk resected cholangiocarcinoma (ACHIEVE): protocol for a phase II, multicentre, randomised controlled trial

Adebrelimab plus capecitabine versus capecitabine monotherapy for adjuvant treatment of high-risk resected cholangiocarcinoma (ACHIEVE): protocol for a phase II, multicentre, randomised controlled trial

Introduction Cholangiocarcinoma (CCA) carries a high risk of recurrence even after curative resection. Capecitabine is standard adjuvant therapy, but recurrence rates remain significant, particularly in high-risk patients. Immunotherapy has shown promise in advanced CCA, prompting investigation into...

Full description

Saved in:
Bibliographic Details
Main Authors: Changxian Li, Xiangcheng Li, Yuan Cheng, Yaodong Zhang
Format: Article
Language:English
Published: BMJ Publishing Group 2025-07-01
Series:BMJ Open Gastroenterology
Online Access:https://bmjopengastro.bmj.com/content/12/1/e001892.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items